Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Biomed Sci ; 27(1): 54, 2020 Apr 17.
Artigo em Inglês | MEDLINE | ID: mdl-32303225

RESUMO

BACKGROUND: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory form of arthritis in which tumor necrosis factor (TNF)-α, a potent inducer of inflammatory response and a key regulator of innate immunity and of Th1 immune responses, plays a central role. NETosis is a mechanism of innate immune defense that is involved in diverse rheumatology diseases. Nevertheless, spontaneous NETosis generation in r-axSpA, its association to disease pathogenesis, and the NETosis involvement on anti-TNF-α therapy's effects has never been explored. METHODS: Thirty r-axSpA patients and 32 healthy donors (HDs) were evaluated. Neutrophil extracellular trap (NET) formation, mediators of signal-transduction cascade required for NETosis induction and cell-free NETosis-derived products were quantified. An additional cohort of 15 r-axSpA patients treated with infliximab (IFX) for six months were further analyzed. In vitro studies were designed to assess the effects of IFX in NETosis generation and the inflammatory profile triggered. RESULTS: Compared to HDs, neutrophils from r-axSpA patients displayed augmented spontaneous NET formation, elevated expression of NET-associated signaling components, nuclear peptidylarginine deiminase 4 translocation and increased citrullinated histone H3. Furthermore, patients exhibited altered circulating levels of cell-free NETosis-derived products (DNA, nucleosomes and elastase). Additional studies revealed that cell-free NETosis-derived products could be suitable biomarkers for distinguish r-axSpA patients from HDs. Correlation studies showed association between cell-free NETosis-derived products and clinical inflammatory parameters. Besides, nucleosomes displayed potential as a biomarker for discriminate patients according to disease activity. IFX therapy promoted a reduction in both NETosis generation and disease activity in r-axSpA patients. Mechanistic in vitro studies further unveiled the relevance of IFX in reducing NET release and normalizing the augmented inflammatory activities promoted by NETs in mononuclear cells. CONCLUSIONS: This study reveals that NETosis is enhanced in r-axSpA patients and identifies the NETosis-derived products as potential disease activity biomarkers. In addition, the data suggests the potential role of NET generation analysis for assessment of therapeutic effectiveness in r-axSpA.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Armadilhas Extracelulares/fisiologia , Infliximab/uso terapêutico , Espondilartrite/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto , Biomarcadores , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Espanha , Espondilartrite/etiologia
2.
Ther Adv Musculoskelet Dis ; 12: 1759720X20982837, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33447266

RESUMO

AIMS: To evaluate the association of estimated cardiovascular (CV) risk and subclinical atherosclerosis with radiographic structural damage in patients with axial spondyloarthritis (axSpA). METHODS: Cross-sectional study including 114 patients axSpA from the SpA registry of Córdoba (CASTRO) and 132 age- and sex-matched healthy controls (HCs). Disease activity and the presence of traditional CV risk factors were recorded. The presence of atherosclerotic plaques and carotid intima media thickness (cIMT) were evaluated through carotid ultrasound and the SCORE index was calculated. Radiographic damage was measured though modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). The association between mSASSS and SCORE was tested using generalized linear models (GLM), and an age-adjusted cluster analysis was performed to identify different phenotypes dependent on the subclinical CV risk. RESULTS: Increased traditional CV risk factors, SCORE, and the presence of carotid plaques were found in axSpA patients compared with HCs. The presence of atherosclerotic plaques and SCORE were associated with radiographic structural damage. The GLM showed that the total mSASSS was associated independently with the SCORE [ß coefficient 0.24; 95% confidence interval (CI) 0.10-0.38] adjusted for disease duration, age, tobacco, C-reactive protein, and non-steroidal anti-inflammatory drugs (NSAID) intake. Hard cluster analysis identified two phenotypes of patients. Patients from cluster 1, characterized by the presence of plaques and increased cIMT, had a higher prevalence of CV risk factors and SCORE, and more structural damage than cluster two patients. CONCLUSION: Radiographic structural damage is associated closely with increased estimated CV risk: higher SCORE levels in axSpA patients were found to be associated independently with mSASSS after adjusting for age, disease duration, CRP, tobacco and NSAID intake.

3.
Arch Microbiol ; 202(2): 309-322, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31659382

RESUMO

In northern Mexico, aridity, salinity and high temperatures limit areas that can be cultivated. To investigate the nature of nitrogen-fixing symbionts of Phaseolus filiformis, an adapted wild bean species native to this region, their phylogenies were inferred by MLSA. Most rhizobia recovered belong to the proposed new species Ensifer aridi. Phylogenetic analyses of nodC and nifH show that Mexican isolates carry symbiotic genes acquired through horizontal gene transfer that are divergent from those previously characterized among bean symbionts. These strains are salt tolerant, able to grow in alkaline conditions, high temperatures, and capable of utilizing a wide range of carbohydrates and organic acids as carbon sources for growth. This study improves the knowledge on diversity, geographic distribution and evolution of bean-nodulating rhizobia in Mexico and further enlarges the spectrum of microsymbiont with which Phaseolus species can interact with, including cultivated bean varieties, notably under stressed environments. Here, the species Ensifer aridi sp. nov. is proposed as strain type of the Moroccan isolate LMR001T (= LMG 31426T; = HAMBI 3707T) recovered from desert sand dune.


Assuntos
Phaseolus/metabolismo , Rhizobiaceae/classificação , Rhizobiaceae/isolamento & purificação , Nódulos Radiculares de Plantas/microbiologia , DNA Bacteriano/genética , Temperatura Alta , México , Phaseolus/crescimento & desenvolvimento , Filogenia , RNA Ribossômico 16S/genética , Rhizobiaceae/genética , Tolerância ao Sal/genética , Areia , Análise de Sequência de DNA , Simbiose
4.
Reumatol. clin., Supl. (Barc.) ; 15(supl.1): 2-6, abr. 2019. ilus
Artigo em Espanhol | IBECS | ID: ibc-184207

RESUMO

Una de las características patogénicas de las espondiloartritis (EspA) es la neoformación ósea. Distintos estudios han puesto de manifiesto que el origen de este proceso está en las entesis, donde algunos factores desen cadenantes, como el estrés biomecánico, en un individuo genéticamente predispuesto producirían una compleja cascada de señales que favorecería la vasodilatación local y la activación de células inmunocompetentes residentes. Estas, a su vez, provocarían una respuesta inflamatoria caracterizada por la secreción de factor de necrosis tumoral alfa e interleucina 17 (IL-17), entre otros, y reclutamiento de otras células inmunocompetentes. Además, se ha demostrado que la IL-17 y la IL-22 favorecen la proliferación de células madre mesenquimatosas del periostio perientesítico, lo que lleva a la formación de hueso nuevo en la entesis. En las EspA, la formación de hueso nuevo es principalmente ortotópica (en continuidad con el hueso existente) y se origina a partir de la entesis y del periostio. Al parecer, la mayoría de la neoformación ósea se produce mediante osificación endocondral. En la osificación endocondral, las células progenitoras mesenquimatosas se diferencian en condrocitos, que construyen un «molde» de cartílago, en el cual las células progresivamente maduran y evolucionan hacia condrocitos hipertróficos. Esta matriz es invadida por vasos y precursores osteoblásticos que reemplazan progresivamente el modelo por hueso maduro


One of the pathogenic characteristics of spondyloarthritis (SpA) is bone neoformation. Several studies have revealed that this process originates in the enthesis, in which triggering factors such as biomechanical stress in genetically predisposed individuals may produce a complex cascade of signals favouring local vasodilation and activation of resident immune cells. These in turn induce an inflammatory response characterised by secretion of TNF-alfa and IL-17 (among other substances) and recruitment of other immune cells. In addition, it has been demonstrated that IL-17 and IL-22 favour the proliferation of mesenchymal stem cells of the peri-enthesic periosteum, leading to the formation of new bone in the enthesis. In SpA, new bone formation is mainly orthotopic (in continuity with existing bone) and arises from the enthesis and periosteum. Most bone neoformation seems to occur through endochondral ossification. In this process, mesenchymal progenitor cells differentiate towards chondrocytes, which construct a cartilaginous "mould" in which the cells progressively mature and develop towards hypertrophic chondrocytes. This matrix is invaded by vessels and osteoblastic precursors that progressively replace the model with mature bone


Assuntos
Humanos , Espondilartrite/fisiopatologia , Osteocondrodisplasias/fisiopatologia , Ossificação Heterotópica/fisiopatologia , Periósteo/fisiopatologia , Osteogênese/fisiologia
5.
Rev Med Inst Mex Seguro Soc ; 52(1): 98-103, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-24625492

RESUMO

BACKGROUND: Loxoscelism is a condition caused by the inoculation of a series of proteolytic enzymes through the loxosceles spider bite (violinist). Morbidity and mortality is unknown in our country. The loxoscelism toxi-syndrome of local expression may have a good prognosis; however, viscera-cutaneus or systemic form has a serious and often fatal evolution. We report a case of a systemic variant developed in a pregnant patient. CLINICAL CASE: We present the first reported case of systemic loxoscelism in a pregnant patient, highlighting the survival of the mother-son, in the presence of viscera-cutaneus behavior. We describe the natural history of clinical expression, highlighting the benefit of current therapeutic antivenom fourth generation and immunoregulation role in supporting the therapeutic approach and the guideline of the surgical approach. CONCLUSIONS: The appropriate multidisciplinary management coupled with an early use of antivenom limits the severity and the potential development of complications. Clinical suspicion is the cornerstone of therapeutic management of these patients.


INTRODUCCIÓN: el loxoscelismo se debe a la inoculación de un conjunto de enzimas proteolíticas por la mordedura de la araña Loxosceles. Puede tener una expresión local, sin embargo, la forma viscerocutánea o sistémica tiene una evolución grave. Se presenta el primer caso de la variante sistémica en una mujer embarazada. CASO CLÍNICO: mujer con embarazo normoevolutivo de 28 semanas. Después de estar expuesta a un ambiente semirrural, presentó placa plana eritematosa en el glúteo derecho, con aumento de la temperatura e hiperestesia local. Fue hospitalizada para administrarle antibióticos parenterales, por considerarse que se trataba de la picadura de un insecto. A las cuatro horas se incrementó el dolor y la paciente desarrolló deshidratación e hipotensión severas hasta llegar al choque, por lo que se inició tratamiento con cristaloides, aminas vasopresoras y protección de la vía aérea. Se realizó operación cesárea, de la que se obtuvo un niño, y se efectuó desbridación en el glúteo derecho. El diagnóstico fue loxoscelismo sistémico, por lo que se administró el antiveneno específico. La paciente fue egresada a los dos meses. CONCLUSIONES: el manejo multidisciplinario oportuno, aunado al empleo del antiveneno, limitó la severidad y el desarrollo potencial de complicaciones. La sospecha clínica es la piedra angular del tratamiento en estos pacientes.


Assuntos
Aranha Marrom Reclusa , Complicações na Gravidez/diagnóstico , Picada de Aranha/diagnóstico , Adulto , Animais , Feminino , Humanos , Gravidez , Complicações na Gravidez/terapia , Picada de Aranha/terapia
6.
Reumatol Clin ; 8 Suppl 1: S26-31, 2012 Mar.
Artigo em Espanhol | MEDLINE | ID: mdl-22418285

RESUMO

TNFalpha inhibitors have been a major advance in the treatment of spondyloarthropathies, having demonstrated their safety and efficacy, with higher response and survival rates than those observed in patients with rheumatoid arthritis. The fact that disease modifying anti-arthritic drugs (DMARD) have shown utility in the treatment of this disease, especially in the axial forms, gives them greater importance, since it is known that up to 30%of patients do not respond to treatment with non-steroidal anti-inflammatory drugs. However, we must take into account that these drugs are expensive and not without side effects, so it is necessary to optimize their use. We intend to review the use of antiTNF alpha in spondyloarthropathies and review the available evidence on strategies that can help with their rational use.


Assuntos
Antirreumáticos/uso terapêutico , Espondilartrite/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Corticosteroides/administração & dosagem , Corticosteroides/uso terapêutico , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Antirreumáticos/efeitos adversos , Ensaios Clínicos como Assunto , Resistência a Medicamentos , Quimioterapia Combinada , Humanos , Terapia de Imunossupressão/efeitos adversos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/tratamento farmacológico , Estudos Multicêntricos como Assunto , Seleção de Pacientes , Guias de Prática Clínica como Assunto , Psoríase/complicações , Psoríase/tratamento farmacológico , Espondilartrite/complicações , Sulfassalazina/administração & dosagem , Sulfassalazina/uso terapêutico , Fatores de Tempo , Uveíte/complicações , Uveíte/tratamento farmacológico
7.
Reumatol. clín. (Barc.) ; 8(supl.1): 26-31, mar. 2012.
Artigo em Espanhol | IBECS | ID: ibc-147108

RESUMO

Los inhibidores del TNFalfa (antiTNFalfa) han supuesto un avance importante en el tratamiento de las espondiloartropatías, habiendo demostrado su eficacia y seguridad, con tasas de respuesta y supervivencia incluso superiores a las observadas en pacientes con artritis reumatoide. El hecho de que los fármacos modificadores de la enfermedad (FAME) no han mostrado utilidad en el tratamiento de esta patología, especialmente en las formas axiales, les confiere mayor importancia, dado que se sabe que hasta el 30% de los pacientes no responden al tratamiento con antiinflamatorios no esteroideos. Sin embargo, hay que tener en cuenta que son fármacos caros y no exentos de efectos secundarios, por lo que es necesario un uso óptimo. Pretendemos hacer una revisión del uso de antiTNFalfa en las espondiloartropatías y se plantean las evidencias disponibles sobre estrategias que puedan ayudar a su uso racional (AU)


TNFalpha inhibitors have been a major advance in the treatment of spondyloarthropathies, having demonstrated their safety and efficacy, with higher response and survival rates than those observed in patients with rheumatoid arthritis. The fact that disease modifying anti-arthritic drugs (DMARD) have shown utility in the treatment of this disease, especially in the axial forms, gives them greater importance, since it is known that up to 30%of patients do not respond to treatment with non-steroidal anti-inflammatory drugs. However, we must take into account that these drugs are expensive and not without side effects, so it is necessary to optimize their use. We intend to review the use of antiTNF alpha in spondyloarthropathies and review the available evidence on strategies that can help with their rational use (AU)


Assuntos
Humanos , Antirreumáticos/efeitos adversos , Antirreumáticos/uso terapêutico , Espondilartrite/complicações , Espondilartrite/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Uveíte/complicações , Uveíte/tratamento farmacológico , Sulfassalazina/administração & dosagem , Sulfassalazina/uso terapêutico , Terapia de Imunossupressão/efeitos adversos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/tratamento farmacológico , Corticosteroides/administração & dosagem , Corticosteroides/uso terapêutico , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Ensaios Clínicos como Assunto , Resistência a Medicamentos , Quimioterapia Combinada , Fatores de Tempo , Estudos Multicêntricos como Assunto , Seleção de Pacientes , Psoríase/complicações , Psoríase/tratamento farmacológico
8.
Gac Med Mex ; 147(3): 195-208, 2011.
Artigo em Espanhol | MEDLINE | ID: mdl-21743587

RESUMO

Mythic, out-dated, ambiguous and sometimes iatrogenic procedures, still remain in pre-hospital and hospital ophidian accident treatment. Errors, omissions and ignorance make ophidian accidents appear more dangerous than they truly are, resulting in a general public contempt toward snakes. Here we present an updated review of current knowledge on pre-hospital and hospital treatment of ophidian bite incidents, including indications, recommendations and logic errors. We describe an appropriate treatment for native Mexican poisonous snakebites using fabotherapics, based on our experience. Adequate initial pre-hospital and hospital management is crucial for a successful outcome of this medical emergency. We describe the state of the art in snake bite research discussing those procedures where research is needed to implement them either by the patient, first responders, paramedics and doctors. We suggest proposals to achieve even more efficient management of fabotherapics based on support networks. Finally, we emphasize prevention as the main subject of venom bite treatment, as it is always more adequate and economic to invest in prevention than to spend on mitigation during emergency and recovery.


Assuntos
Serviços Médicos de Emergência , Mordeduras de Serpentes/diagnóstico , Mordeduras de Serpentes/terapia , Algoritmos , Antivenenos/uso terapêutico , Humanos
9.
Reumatol. clín. (Barc.) ; 6(supl.1): 11-17, mar. 2010. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-148860

RESUMO

Las recomendaciones del Ankylosing Spondylitis Working Group (grupo ASAS) y del Consenso de la Sociedad Española de Reumatología para el tratamiento de las espondiloartritis con inhibidores del factor de necrosis tumoral aconsejan evaluar la movilidad espinal entre las medidas de respuesta al tratamiento. Es conocida la variabilidad clínica entre los reumatólogos al realizar este tipo de determinaciones. Recientemente, el grupo GRESSER ha creado en nuestro país una escuela para mejorar entre los reumatólogos el conocimiento en el área de las espondiloartritis. Uno de sus objetivos es la estandarización en la forma de realizar las mediciones en este grupo de enfermedades. Este documento resume la actividad desarrollada en un reciente taller con una detallada descripción de los procedimientos seguidos para cumplir cada una de las mediciones importantes que afectan al esqueleto axial. Con este texto esperamos contribuir a la deseada estandarización en el campo de la metrología de las espondiloartritis (AU)


The ASAS group recommendations as well as those from the SER consensus for the treatment of spondyloarthritis with TNF inhibitors advise for the performance of spinal motility tests among the response to treatment measures. The clinical variability between rheumatologists when performing these types of measurements is well documented. Recently, the GRESSER group in our country has created a school to improve knowledge in the area of spondyloarthritis among rheumatologists. One of their objectives is the standardization in the ways measurements are performed in this group of diseases. This document summarizes the activities developed in a recent workshop with a detailed description of the procedures followed to perform each one of the important measurements affecting the axial skeleton. With this we hope to contribute to the much desired standardization in the field of metrology in spondyloarthritis (AU)


Assuntos
Humanos , Espondilartrite/fisiopatologia , Fator 1 Associado a Receptor de TNF/antagonistas & inibidores , Destreza Motora/fisiologia , Índice de Gravidade de Doença , Exame Físico/métodos , Fenômenos Biomecânicos/fisiologia
10.
Reumatol Clin ; 6 Suppl 1: 11-7, 2010 Mar.
Artigo em Espanhol | MEDLINE | ID: mdl-21794747

RESUMO

The ASAS group recommendations as well as those from the SER consensus for the treatment of spondyloarthritis with TNF inhibitors advise for the performance of spinal motility tests among the response to treatment measures. The clinical variability between rheumatologists when performing these types of measurements is well documented. Recently, the GRESSER group in our country has created a school to improve knowledge in the area of spondyloarthritis among rheumatologists. One of their objectives is the standardization in the ways measurements are performed in this group of diseases. This document summarizes the activities developed in a recent workshop with a detailed description of the procedures followed to perform each one of the important measurements affecting the axial skeleton. With this we hope to contribute to the much desired standardization in the field of metrology in spondyloarthritis.

11.
Syst Appl Microbiol ; 29(7): 526-38, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16413160

RESUMO

Sixty-eight new rhizobial isolates were obtained from root-nodules of Medicago laciniata and from Mediterranean soils in Tunisia and France. All of them were identified as Sinorhizobium meliloti on the basis of PCR-RFLP analyses of 16S rDNA and the intergenic spacer sequence between 16S and 23S rDNAs. DNA/DNA hybridization, phenotypic characterization and 16S rRNA gene sequencing led to the conclusion that they belong the same taxon. All new isolates shared the ability to nodulate and fix nitrogen with M. laciniata except 11 of them not capable of fixing nitrogen with this plant and originating from French soils containing no efficiently adapted symbionts with M. laciniata. The nitrogen-fixing rhizobia on M. laciniata differed markedly from the other S. meliloti or Sinorhizobium medicae isolates and references in their symbiotic traits such as nifDK RFLP diversity, nodA sequences and nitrogen effectiveness with tree other different annual Medicago species (M. truncatula, M. polymorpha and M. sauvagei). Two infrasubspecific (biovar) divisions are therefore proposed within S. meliloti: bv. medicaginis for Sinorhizobium efficient on M. laciniata and bv. meliloti for the classically known S. meliloti group represented by the strains ATCC9930(T) and RCR 2011 efficient on M. sativa.


Assuntos
Medicago/microbiologia , Fixação de Nitrogênio/fisiologia , Sinorhizobium meliloti/classificação , Aciltransferases/química , Aciltransferases/genética , Proteínas de Bactérias/química , Proteínas de Bactérias/genética , Sequência de Bases , DNA Bacteriano/química , DNA Bacteriano/genética , DNA Espaçador Ribossômico/química , DNA Espaçador Ribossômico/genética , França , Variação Genética , Dados de Sequência Molecular , Hibridização de Ácido Nucleico , Fenótipo , Filogenia , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de Restrição , RNA Ribossômico 16S/química , RNA Ribossômico 16S/genética , Nódulos Radiculares de Plantas/microbiologia , Análise de Sequência de DNA , Sinorhizobium meliloti/genética , Sinorhizobium meliloti/isolamento & purificação , Sinorhizobium meliloti/metabolismo , Simbiose/fisiologia , Tunísia
12.
Curr Med Res Opin ; 20(2): 155-7, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15006008

RESUMO

OBJECTIVE: To study the local and systemic levels of the tumour necrosis factor-alpha in patients with active uveitis and to determine the implication of TNF-alpha in rheumatological uveitis and to observe if this relationship is more significant in the B27 positive patients. PATIENTS AND METHODS: Patients were selected on the basis of a diagnosis of uveitis of any aetiology. Data from 23 patients were stratified into two categories according to the presence or absence of systemic rheumatic disease. The first group comprised nine patients with rheumatic disease; the second group contained 14 patients without rheumatic disease. The patients were also sub-classified into those who were HLA-B27 positive (14 patients) and those who were not. TNF-alpha levels in serum and aqueous humour from a group of 16 patients with uncomplicated cataracts were analysed as a control group. RESULTS: In the control group (n = 16) the serum TNF-alpha concentration was 13.1 +/- 2.9 pg/ml and the aqueous humour concentration of TNF-alpha was 0.56 +/- 1.53 pg/ml. In uveitis patients (n = 23) the serum TNF-alpha concentration was 35.35 +/- 26.77 pg/ml and the aqueous humour concentration of TNF-alpha was 15.1 +/- 1.70 pg/ml (p < 0.01). In HLA-B27 positive patients (n = 9) the serum TNF-alpha concentration was 45.56 +/- 34.17 pg/ml and the aqueous humour concentration of TNF-alpha was 15.89 +/- 0.93 pg/ml. In HLA-B27 negative patients (n = 14) the serum TNF-alpha concentration was 28.79 +/- 19.38 pg/ml and aqueous humour concentration of TNF-alpha was 14.57 +/- 1.91 pg/ml (p < 0.01). CONCLUSIONS: The concentration of TNF-alpha in aqueous humour in patients who are HLA-B27 positive is significantly greater than in those who are B27 negative. No significant differences in the concentrations of TNF-alpha in serum or aqueous humour in patients with or without rheumatic diseases were detected. TNF-alpha is a cytokine that may participate actively in the pathogenesis of clinical uveitis.


Assuntos
Antígeno HLA-B27/sangue , Fator de Necrose Tumoral alfa/metabolismo , Uveíte/imunologia , Humor Aquoso/metabolismo , Estudos de Casos e Controles , Humanos , Estatísticas não Paramétricas
13.
Arch Cardiol Mex ; 72 Suppl 1: S247-53, 2002.
Artigo em Espanhol | MEDLINE | ID: mdl-12001856

RESUMO

The goal of cardiac rehabilitation is to incorporate patients with heart disease into their physical and social activities in such conditions that will allow them to lead a normal life "as good as possible". Their psychological needs have to be addressed, since these patients on leaving the hospital are anxious and afraid of the their future. The rehabilitation team must train the patients until they reach with success phase II of the heart rehabilitation program. The nurse plays and important role since she/he is the main mentor during phase II. At the cardiac rehabilitation service of the Instituto Nacional de Cardiología "Ignacio Chávez", we worked during May, June, July of last year with 45 patients in phase II; of these, 84% were men, most between 60 and 79 years of age (60%). The most frequent diagnoses were ischemic cardiopathy (71%) and arterial hypertension (64%). The most frequent medical-surgical treatments were: thrombolytic therapy, angioplasty, and placement of stents and aortic-coronary ducts in 48%. Stratification was of high risk in 62.2%.


Assuntos
Cardiopatias/enfermagem , Cardiopatias/reabilitação , Humanos
14.
Cochabamba; UMSS-Fac. Agronomía. TESIS; 1995. 62 ; 28 cm p. graf.
Tese em Espanhol | LIBOCS, LIBOSP | ID: biblio-1334971

Assuntos
Bolívia , Medicago
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...